New Pulmonary Indication
Kalydeco (ivacaftor)
Indication for cystic fibrosis now includes 33 CFTR gene mutations.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.
Comments